Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background and purpose: Duchenne muscular dystrophy (DMD) is a severe muscle wasting disorder caused by the absence of the cytoskeletal protein dystrophin. This leads to muscle cell death accompanied by chronic inflammation. Cyclosporin A (CsA) is a powerful immunosuppressive drug, which has been proposed for DMD treatment. CsA also directly regulates the mitochondrial permeability transition pore (mPTP), which participates in cell death pathways through the inhibition of cyclophilin D. Here, we evaluated whether Debio 025, a cyclophilin inhibitor with no immunosuppressive activity, improves the dystrophic condition in a mouse model of DMD, through regulation of mPTP. Experimental approach: The potency of Debio 025 to protect mouse dystrophic cells against mitochondria‐mediated death was assessed by caspase‐3 activity and calcium retention capacity assays.Mdx5Cvmice (3‐week‐old) were treated daily by gavage for 2 weeks with Debio 025 (10, 30 or 100 mg kg−1), CsA (10 mg kg−1) or placebo. The effects on muscle necrosis and function were measured. Key results: In vitro investigations showed protective effect of low concentrations of Debio 025 against cell death. Histology demonstrated that Debio 025 partially protected the diaphragm and soleus muscles against necrosis (10 and 100 mg kg−1, respectively). Hindlimb muscles from mice receiving Debio 025 at 10 mg kg−1 relaxed faster, showed alteration in the stimulation frequency‐dependent recruitment of muscle fibres and displayed a higher resistance to mechanical stress. Conclusions and implications: Debio 025 partially improved the structure and the function of the dystrophic mouse muscle, suggesting that therapies targeting the mPTP may be helpful to DMD patients. British Journal of Pharmacology(2008)155, 574–584; doi:10.1038/bjp.2008.285; published online 21 July 2008
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Skeletal muscle fatigue: cellular mechanisms
Allen, D. G., Lamb, G. D., & Westerblad, H. (2008) · Physiological Reviews · doi:10.1152/physrev.00015.2007 · Cited by 2,495
The mitochondrial permeability transition pore and its role in cell death
CROMPTON, M. (1999) · Biochemical Journal · doi:10.1042/bj3410233 · Cited by 2,432 · cited 1×
“Indeed, pore opening can be promoted by a high concentration of matrix Ca2þ levels, oxidative stress, pyridine nucleotide oxidation, thiol oxidation, alkalinization or low transmembrane potential (Bernardi, 1999; Crompton, 1999).”
BackgroundBaines, C. P., Kaiser, R. A., Purcell, N. H., Blair, N. S., Osinska, H., Hambleton, M. A., Brunskill, E. W., Sayen, M. R., Gottlieb, R. A., Dorn, G. W., et al. (2005) · Nature · doi:10.1038/nature03434 · Cited by 2,280
Nakagawa, T., Shimizu, S., Watanabe, T., Yamaguchi, O., Otsu, K., Yamagata, H., Inohara, H., Kubo, T., & Tsujimoto, Y. (2005) · Nature · doi:10.1038/nature03317 · Cited by 1,635 · cited 11×
“Because Debio 025 is capable of selectively and strongly inhibiting CyPD (Gomez et al., 2007), we hypothesized that this compound would block the mPTP, prevent cell death and reduce muscle wasting.”
BackgroundInfluentialDystrophin protects the sarcolemma from stresses developed during muscle contraction
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., & Sweeney, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3710 · Cited by 1,526
Properties of the Permeability Transition Pore in Mitochondria Devoid of Cyclophilin D
Basso, E., Fante, L., Fowlkes, J., Petronilli, V., Forte, M. A., & Bernardi, P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500089200 · Cited by 808 · cited 11×
“Because Debio 025 is capable of selectively and strongly inhibiting CyPD (Gomez et al., 2007), we hypothesized that this compound would block the mPTP, prevent cell death and reduce muscle wasting.”
BackgroundInfluentialCai, J., & Jones, D. P. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.19.11401 · Cited by 765 · cited 2×
“…is a potent protein kinase inhibitor with a broad spectrum of activities (Ruegg and Burgess, 1989), known to induce apoptosis through a mitochondrial pathway (Yang et al., 1997) and to cause oxidative stress through generation of reactive oxygen species (Cai and Jones, 1998; Kruman et al., 1998).”
BackgroundThe mitochondrial permeability transition from in vitro artifact to disease target
Bernardi, P., Krauskopf, A., Basso, E., Petronilli, V., Blalchy‐Dyson, E., Di Lisa, F., & Forte, M. A. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05213.x · Cited by 627
The Mitochondrial Permeability Transition, Release of Cytochrome c and Cell Death
Petronilli, V., Penzo, D., Scorrano, L., Bernardi, P., & Di Lisa, F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010604200 · Cited by 472 · cited 2×
“5 kDa, which may cause swelling, cristae unfolding and outer membrane rupture associated with the release of cytochrome c and pro-apoptotic factors (Petronilli et al., 2001).”
BackgroundInfluentialPharmacological strategies for muscular dystrophy
Khurana, T. S., & Davies, K. E. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1085 · Cited by 225 · cited 2×
“Recently, with increasing knowledge of the mechanisms underlying the disease process, new therapeutic approaches have been proposed as palliative treatments for DMD, essentially based on investigations using the dystrophic mdx (muscular dystrophy X-linked) mouse model (Khurana and Davies, 2003; Chakkalakal et al., 200…”
Background
Cited by
Bernardi, P., Rasola, A., Forte, M., & Lippe, G. (2015) · Physiological Reviews · doi:10.1152/physrev.00001.2015 · Cited by 577
Molecular mechanisms and consequences of mitochondrial permeability transition
Bonora, M., Giorgi, C., & Pinton, P. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00433-y · Cited by 538
Ischemia/Reperfusion Injury Revisited: An Overview of the Latest Pharmacological Strategies
Soares, R. O. S., Losada, D. M., Jordani, M. C., Évora, P., & Castro-e-Silva, O. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205034 · Cited by 408
Physiologic Functions of Cyclophilin D and the Mitochondrial Permeability Transition Pore
Elrod, J. W., & Molkentin, J. D. (2013) · Circulation Journal · doi:10.1253/circj.cj-13-0321 · Cited by 266
AMPK Activation Stimulates Autophagy and Ameliorates Muscular Dystrophy in the mdx Mouse Diaphragm
Pauly, M., Daussin, F., Burelle, Y., Li, T., Godin, R., Fauconnier, J., Koechlin-Ramonatxo, C., Hugon, G., Lacampagne, A., Coisy-Quivy, M., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.04.004 · Cited by 225
Physiopathology of the Permeability Transition Pore: Molecular Mechanisms in Human Pathology
Bonora, M., Patergnani, S., Ramaccini, D., Morciano, G., Pedriali, G., Kahsay, A., Bouhamida, E., Giorgi, C., Wieckowski, M., & Pinton, P. (2020) · Biomolecules · doi:10.3390/biom10070998 · Cited by 135
Carraro, M., Carrer, A., Urbani, A., & Bernardi, P. (2020) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.05.014 · Cited by 71
Bencze, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010362 · Cited by 20
Metadata
- Authors
- Reutenauer, J., Dorchies, O. M., Patthey‐Vuadens, O., Vuagniaux, G., & Ruegg, U. T.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2008-10
- Volume
- 155
- Issue
- 4
- Pages
- 574-584
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1604011996
- Cited by
- 102
- References
- 10
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.